Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norway to reimburse liquid-based cytology for cervical cancer screening

This article was originally published in Clinica

Executive Summary

The Norwegian cervical screening programme has begun reimbursing liquid-based cytology (LBC), paving the way for this technique to replace the traditional Pap test. During a Pap test, a cervical sample is smeared onto a slide and then analysed. LBC samples are collected in a similar way, but the cervical cells are rinsed off into a vial of preservative fluid before being sent to the lab. The method could reduce the number of inadequate samples and, consequently, the number of women who need to return for repeat testing. The UK converted to LBC testing in 2008 (www.clinica.co.uk, 9 May 2008). Available LBC tests include Hologic's ThinPrep and Source BioScience Healthcare's SurePath system.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel